Coherus BioSciences, Inc. (CHRS)
Market Cap | 659.56M |
Revenue (ttm) | 239.06M |
Net Income (ttm) | -278.61M |
Shares Out | 77.78M |
EPS (ttm) | -3.59 |
PE Ratio | n/a |
Forward PE | 32.89 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 83,775 |
Open | 8.45 |
Previous Close | 8.48 |
Day's Range | 8.34 - 8.55 |
52-Week Range | 5.58 - 14.11 |
Beta | 0.87 |
Analysts | Buy |
Price Target | 18.11 (+113.31%) |
Earnings Date | Feb 16, 2023 |
About CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab bios... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for CHRS stock is "Buy." The 12-month stock price forecast is $18.11, which is an increase of 113.31% from the latest price.
News

Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential

Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming 41st Annual J.P. Morgan...

Coherus BioSciences (CHRS) Reports Q3 Loss, Lags Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -81.13% and 20.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc...

Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
– UDENYCA® net sales of $45.4 million in the third quarter 2022 – – CIMERLI™ launched in the United States on October 3 rd – – Planning underway for 2023 commercial launches of toripalimab, YUSIMRY™ a...

Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2022 financial results will be released after market...

Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022
- CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis ® (ranibizumab injection) for all indications, with 12 months of interchangeability exclusivity -

Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference
REDWOOD CITY, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will participate at the H.C. Wainwright 24th Annual...

Here's Why Coherus BioSciences (CHRS) Looks Ripe for Bottom Fishing
Coherus BioSciences (CHRS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement ...

Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 24, 2022, the compensation committee...

Wall Street Analysts Think Coherus BioSciences (CHRS) Could Surge 47%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 47.3% in Coherus BioSciences (CHRS). While the effectiveness of this highly sought-after metric is questionable...

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 32.29% and 3.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update
– Commercial launch of CIMERLI™ planned for early October 2022 – – PDUFA date for toripalimab BLA is December 23, 2022 – – Commercial preparation underway for planned July 2023 launch of YUSIMRY™ – – ...

Wall Street Analysts Predict an 85% Upside in Coherus BioSciences (CHRS): Here's What You Should Know
The consensus price target hints at an 84.6% upside potential for Coherus BioSciences (CHRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni...

FDA Approves Coherus' CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity
- CIMERLI™ is Coherus' third FDA-approved product and the first of four new product launches planned by the end of 2023 -

Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022
REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after marke...

Coherus BioSciences Appoints Dr. Jill O'Donnell-Tormey to its Board of Directors
- Dr. O'Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute's efforts to advance cancer immunotherapies -

Coherus BioSciences Management to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in...

Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -55% and 11.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Coherus BioSciences Reports First Quarter 2022 Results
– CIMERLI ™ BLA review progressing toward August 2022 action date – – Toripalimab BLA resubmission expected by mid-summer – – UDENYCA® delivers 1 st quarter 2022 net sales of $60.1 million – – 2022 R&...

Coherus BioSciences Appoints Charlie Newton to Board of Directors
- Biotechnology Chief Financial Officer and highly regarded former healthcare investment banker brings decades of industry experience to Coherus' immuno-oncology strategy execution -

FDA Rejects Junshi - Coherus' Toripalimab For Rare Head & Neck Cancer
The FDA has issued a complete response letter (CRL) to Junshi Biosciences Co Ltd and Coherus BioSciences Inc's (NASDAQ: CHRS) toripalimab application for advanced recurrent or metastatic nasopharyngea...

CORRECTION - Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022
REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Coherus BioSciences, Inc. (Nasdaq: CHRS), please note in the Conference Call Infor...

Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022
REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its first quarter 2022 financial results will be released after the c...

Coherus BioSciences (CHRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 Biotech Stocks to Buy With Key Catalysts for April
Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies bel...